BofA raised the firm’s price target on Argenx (ARGX) to $670 from $610 and keeps a Buy rating on the shares after a “solid” Q3 beat driven by strong continued growth in gMG. The firm is “highly encouraged” by the continued strong cadence of the Vyvgart launch in gMG, which gives it confidence that the commercial opportunity is larger than we thought, the analyst tells investors.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX: